KOPS - Das Institutionelle Repositorium der Universität Konstanz

Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists

Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists

Zitieren

Dateien zu dieser Ressource

Prüfsumme: MD5:547c38a742d93a1f94d0e417f90e5f09

HEESEN, Christoph, Ingo KLEITER, Franziska NGUYEN, Nina SCHÄFFLER, Jürgen KASPER, Sascha KÖPKE, Wolfgang GAISSMAIER, 2010. Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists. In: Multiple Sclerosis. 16(12), pp. 1507-1512. ISSN 1352-4585. eISSN 1477-0970. Available under: doi: 10.1177/1352458510379819

@article{Heesen2010-12perce-28032, title={Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists}, year={2010}, doi={10.1177/1352458510379819}, number={12}, volume={16}, issn={1352-4585}, journal={Multiple Sclerosis}, pages={1507--1512}, author={Heesen, Christoph and Kleiter, Ingo and Nguyen, Franziska and Schäffler, Nina and Kasper, Jürgen and Köpke, Sascha and Gaissmaier, Wolfgang} }

Kleiter, Ingo Köpke, Sascha Multiple Sclerosis ; 16 (2010), 12. - S. 1507-1512 Nguyen, Franziska Schäffler, Nina 2010-12 Schäffler, Nina Nguyen, Franziska 2014-07-04T08:39:17Z Köpke, Sascha Kasper, Jürgen eng Gaissmaier, Wolfgang 2014-07-04T08:39:17Z Background:<br />Natalizumab is associated with the potentially life-threatening side-effect progressive multifocal leukoence- phalopathy (PML). Little is known about patients' and physicians' risk estimates and attitudes towards natalizumab treatment.<br /><br />Methods:<br />Consecutive natalizumab-treated patients (n = 69) and neurologists (n = 66) in two centres and cooperating private practices received an evidence-based three-page information leaflet about natalizumab-associated PML and an evaluation sheet.<br /><br /><br />Results:<br />After reading the information, patients were significantly more likely than physicians to intend continuation of natalizumab treatment and willing to accept higher risks of PML: 49% of physicians would stop treatment at a PML risk of 2 : 10,000 or lower, while only 17% of patients would do so (p < 0.001). This difference could not be explained by risk calculation abilities or lack of understanding. Both groups overestimated natalizumab treatment effects.<br /><br /><br />Conclusion:<br />Patients had a significantly worse perception of multiple sclerosis as a malignant disease. We conclude that patients were willing to accept a higher risk of PML than neurologists. Coherent with their perception of risks and benefits, patients were also more willing to continue treatment. Open information about treatment-related risks is appreciated and might support shared decision making. Heesen, Christoph Heesen, Christoph Gaissmaier, Wolfgang deposit-license Kleiter, Ingo Kasper, Jürgen Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists

Dateiabrufe seit 01.10.2014 (Informationen über die Zugriffsstatistik)

Heesen_280329.pdf 602

Das Dokument erscheint in:

KOPS Suche


Stöbern

Mein Benutzerkonto